Pharmaceutical Commerce - July/August 2013 - (Page 8)

Top News IMS Use of Medicines report: 2012 sales drop 1.0%—the first ever recorded decline Annual study sees the end of the “generics bubble” and worrisome trends in consumer utilization of healthcare The annual analysis from the IMS Health Informatics Institute (Parsippany, NJ) calculates overall US spending on pharmaceutical products at $325.8 billion in 2012—the first annual decline IMS has reported since beginning the study in 1957. In other contexts, a reversal like that would be a startling development, but in this case, most forecasters could see that with the rise of patent expiries (the so-called “patent cliff,” which, from the other side of the ledger, IMS is calling the “generics bubble”), the thin pipeline of new products and the overall pressure on both healthcare costs and demonstrable health outcomes, a slowdown in pharma sales has long been expected. And this decline is already reversing itself: FDA approved 39 new molecular entities in 2012 (28 of which were introduced into the market); the cost of loss of exclusivity on patented drugs has peaked at 2012’s $28.9 billion, and will decline in the next few years. IMS Institute projects that pharma sales will be flat in 2013 (0–1% growth), but then begin climbing again in 2014 (4–5% growth). “Lots of analysts are focused on the impact of Obamacare, which kicks in in 2014,” notes Michael Kleinrock, director at the Institute, “but we see it as a combination of the new patients that Obamacare will bring in as well as fewer patent expirations.” Patent expirations over the past five years have removed $75 billion in pharma sales; over the next few years, the growth of specialty pharmaceutical spending (calculated at $87 billion in 2012 by IMS) will become “the focus of discussion,” says Kleinrock. Pharmaceuticals are a declining part of overall healthcare spending—but there are some worrisome trends hidden within that. The number of office visits by patients declined in 2012, continuing a trend of several years. At the same time, the out-of-pocket expenses by patients is rising—for commercially insured under age 65, they reached $1,146 in 2012, a 30% jump in one year. Per capita usage of pharmaceuticals declined by 0.1% (although overall prescription growth was 1.2%). “One can assume that managed care is removing unnecessary costs from healthcare, but the higher out-of-pocket costs might also be removing patients with chronic conditions from getting necessary healthcare—and that could result in higher healthcare costs down the road,” says Kleinrock. Channel trends The IMS report also provides data on pharmaceutical distribution by channel. In 2012, a decline in chain-pharmacy sales (-3.1%) was almost matched by an increase in mail order (+3.0%). Independents saw a decline in sales (-1.0%), reversing a near-term growth trend of the past two years— and the number of prescriptions filled at independents also declined by the same percentage. Food store pharmacies remained absolutely flat. Among institutional channels, clinics showed a 1.8% increase, while most others were flat or declining. There is an influence of the drug mix to be seen here: “Long term care is heavily dependent on cardiovascular and mental-health drugs, and both of those experienced significant patent expiries,” notes Kleinrock. The full report, “Declining Medicine Use and Costs: For Better or Worse,” is available at the IMS Institute website. Data are derived from IMS’ National Sales Perspectives, National Prescription Audit and other reports; pharma pricing is reported ex-manufacturer and does not include offinvoice rebates and discounting. The report is published with no industry or institutional support. More cold-chain facilities open up around the world Panalpina, LuxairCargo, UPS have new warehouse capacity; DHL upgrades facilities and depots for life sciences shipping Ribbon-cutting at Panalpina’s new San Juan, PR, facility. (left to right): Ralph Riehl, managing director, Panalpina USA; Lic Alberto Baco, secretary of economic development, Puerto Rico; Ricardo Ortiz, business unit manager, Panalpina San Juan; Waleska Rivera, president, Puerto Rico Manufacturing Assn.; Ferdinand Kurt, CEO, Panalpina Americas Region. Credit: Panalpina On May 16, Panalpina cut the ribbon on an expansion of its existing, 37,000-sq. ft. logistics center in San Juan, PR, to include validated cold-chain storage, in a multi-zoned controlled refrigeration space. Promoted as “the coolest spot in the Caribbean,” the 6,000-sq. ft. facility will handle healthcare products and related chemical trans-shipments, and is two miles from the San Juan International Airport. Panalpina can arrange dedicated flights for shippers from there, as well as connect San Juan to the global “own controlled air freight network” that Panalpina operates. Few third-party logistics firms operate their own air fleet; Panalpina, which also has extensive ocean and ground transportation globally, has exclusive leases on a group of B-747 aircraft to handle its own international cargo. The fleet has a geographically diverse range of regular runs between Europe, North and South America, and a variety of locations in Asia. The San Juan facility has onsite customs services, cross-dock and consolidation capabilities, and kitting and pick-and-pack services. Panalpina is also certified under the QEP program, operated by refrigerated-container supplier Envirotainer, for managing shipments protected by the latter’s storage devices. Earlier this spring, LuxairCargo, which operates out of the Luxembourg airport (and is, in fact, the only freight handler there) opened a 3,000-sq.m. facility, expressly for 8 Visit our website at www.PharmaceuticalCommerce.com July | August 2013 pharma and healthcare products. The space is subdivided into 2–8°C, 15–25°C and 2–25°C spaces, including a temperaturecontrolled setup zone and temperature-controlled truck docks. LuxairCargo says that the space, and the staff that runs it, is “totally” compliant with the 2013 GDP guidelines. Also in Europe, CEVA Logistics (Milan) has opened what Craig Foster, senior VP of UPS Asia Pacific Healthcare and supply chain logistics; Richard Loi, president of UPS China; Brendan Canavan, president of UPS Asia Pacific Region; Jim Barber, president of UPS International; Wu Ningyi, deputy general director of Zhejiang FDA; Zhao Liming, vice governor of Xiaoshan; Lou Zengming, general director of Linjiang Industry Zone http://www.PharmaceuticalCommerce.com

Table of Contents for the Digital Edition of Pharmaceutical Commerce - July/August 2013

Pharmaceutical Commerce - July/August 2013
Editorial
Contents
Op-Ed
Top News
Business/Finance
Brand Marketing & Communications
Supply Chain/Logistics
Information Technology
Manufacturing & Packaging
Legal & Regulatoryv
Meetings and Editorial Index

Pharmaceutical Commerce - July/August 2013

http://www.nxtbook.com/nxtbooks/pharmcomm/201911
http://www.nxtbook.com/nxtbooks/pharmcomm/201909
http://www.nxtbook.com/nxtbooks/pharmcomm/201906
http://www.nxtbook.com/nxtbooks/pharmcomm/201903
http://www.nxtbook.com/nxtbooks/pharmcomm/201811
http://www.nxtbook.com/nxtbooks/pharmcomm/201809
http://www.nxtbook.com/nxtbooks/pharmcomm/201806
http://www.nxtbook.com/nxtbooks/pharmcomm/20180304
http://www.nxtbook.com/nxtbooks/pharmcomm/20171112
http://www.nxtbook.com/nxtbooks/pharmcomm/20170910
http://www.nxtbook.com/nxtbooks/pharmcomm/20170708
http://www.nxtbook.com/nxtbooks/pharmcomm/20170506
http://www.nxtbook.com/nxtbooks/pharmcomm/20170304
http://www.nxtbook.com/nxtbooks/pharmcomm/20170102
http://www.nxtbook.com/nxtbooks/pharmcomm/20161112
http://www.nxtbook.com/nxtbooks/pharmcomm/20160910
http://www.nxtbook.com/nxtbooks/pharmcomm/20160708
http://www.nxtbook.com/nxtbooks/pharmcomm/20160506
http://www.nxtbook.com/nxtbooks/pharmcomm/20160304
http://www.nxtbook.com/nxtbooks/pharmcomm/20160102
http://www.nxtbook.com/nxtbooks/pharmcomm/20151112
http://www.nxtbook.com/nxtbooks/pharmcomm/20150910
http://www.nxtbook.com/nxtbooks/pharmcomm/20150708
http://www.nxtbook.com/nxtbooks/pharmcomm/20150506
http://www.nxtbook.com/nxtbooks/pharmcomm/20150304
http://www.nxtbook.com/nxtbooks/pharmcomm/20150102
http://www.nxtbook.com/nxtbooks/pharmcomm/20141112
http://www.nxtbook.com/nxtbooks/pharmcomm/coldchaindirectory2014
http://www.nxtbook.com/nxtbooks/pharmcomm/20140910
http://www.nxtbook.com/nxtbooks/pharmcomm/20140708
http://www.nxtbook.com/nxtbooks/pharmcomm/20140506
http://www.nxtbook.com/nxtbooks/pharmcomm/20140304
http://www.nxtbook.com/nxtbooks/pharmcomm/20140102
http://www.nxtbook.com/nxtbooks/pharmcomm/dataservicedirectory
http://www.nxtbook.com/nxtbooks/pharmcomm/20131112
http://www.nxtbook.com/nxtbooks/pharmcomm/20130910_hubreport
http://www.nxtbook.com/nxtbooks/pharmcomm/20130910
http://www.nxtbook.com/nxtbooks/pharmcomm/20130708
http://www.nxtbook.com/nxtbooks/pharmcomm/20130506
http://www.nxtbook.com/nxtbooks/pharmcomm/coldchain2013
http://www.nxtbook.com/nxtbooks/pharmcomm/20130304
http://www.nxtbook.com/nxtbooks/pharmcomm/20130102
http://www.nxtbook.com/nxtbooks/pharmcomm/20121112
http://www.nxtbook.com/nxtbooks/pharmcomm/20120910
http://www.nxtbook.com/nxtbooks/pharmcomm/20120708
http://www.nxtbook.com/nxtbooks/pharmcomm/20120506
http://www.nxtbook.com/nxtbooks/pharmcomm/20120506_coldchain
http://www.nxtbook.com/nxtbooks/pharmcomm/20120304
http://www.nxtbook.com/nxtbooks/pharmcomm/20120102
http://www.nxtbook.com/nxtbooks/pharmcomm/20111112
http://www.nxtbook.com/nxtbooks/pharmcomm/20110910
http://www.nxtbook.com/nxtbooks/pharmcomm/20110708
http://www.nxtbook.com/nxtbooks/pharmcomm/20110506
http://www.nxtbook.com/nxtbooks/pharmcomm/20110304
http://www.nxtbook.com/nxtbooks/pharmcomm/20110102
http://www.nxtbook.com/nxtbooks/pharmcomm/20101112
http://www.nxtbook.com/nxtbooks/pharmcomm/20100910
http://www.nxtbook.com/nxtbooks/pharmcomm/20100708
http://www.nxtbook.com/nxtbooks/pharmcomm/20100506
http://www.nxtbook.com/nxtbooks/pharmcomm/201004
http://www.nxtbook.com/nxtbooks/pharmcomm/201003
http://www.nxtbook.com/nxtbooks/pharmcomm/20100102
http://www.nxtbook.com/nxtbooks/pharmcomm/20091112
http://www.nxtbookMEDIA.com